Intervention Review

Risperidone versus other atypical antipsychotic medication for schizophrenia

  1. Simon Gilbody1,*,
  2. Anne-Marie Bagnall2,
  3. Lorna Duggan3,
  4. Arja Tuunainen4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 24 JUL 2000

Assessed as up-to-date: 23 MAY 2000

DOI: 10.1002/14651858.CD002306


How to Cite

Gilbody S, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD002306. DOI: 10.1002/14651858.CD002306.

Author Information

  1. 1

    University of York, Department of Health Sciences, York, UK

  2. 2

    Leeds Metropolitan University, Faculty of Health, Leeds, UK

  3. 3

    Care Principles Ltd, Newmarket, Suffolk, UK

  4. 4

    University of Helsinki, Department of Psychiatry, Hus, Finland

*Simon Gilbody, Department of Health Sciences, University of York, Seebohm Rowntree Building, York, YO10 5DD, UK. sg519@york.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JUL 2000

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lamiae Grimaldi-Bensouda, Frederic Rouillon, Bernard Astruc, Michel Rossignol, Jacques Benichou, Bruno Falissard, Frederic Limosin, Beatrice Beaufils, Guillaume Vaiva, Helene Verdoux, Yola Moride, Alban Fabre, Florence Thibaut, Lucien Abenhaim, Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS), Schizophrenia Research, 2012, 134, 2-3, 187

    CrossRef

  2. 2
    John Wong, Wanwen Lan, Li Ming Ong, Louis Tong, Non-hormonal Systemic Medications and Dry Eye, The Ocular Surface, 2011, 9, 4, 212

    CrossRef

  3. 3
    Join Y. Luh, Atypical Antipsychotic Drugs for Schizophrenia, Mayo Clinic Proceedings, 2003, 78, 3, 381

    CrossRef

  4. 4
    Robin Emsley, Piet Oosthuizen, The new and evolving pharmacotherapy of schizophrenia, Psychiatric Clinics of North America, 2003, 26, 1, 141

    CrossRef

  5. 5
    Seiya Miyamoto, David B. Merrill, L. Fredrik Jarskog, W. Wolfgang Fleishhacker, Stephen R. Marder, Jeffrey A. Lieberman, Antipsychotic Drugs,
  6. 6
    Claudia Asenjo Lobos, Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Stefan Leucht, Clozapine versus other atypical antipsychotics for schizophrenia, The Cochrane Library,
  7. 7
    Abraham M Nussbaum, T S Stroup, Oral paliperidone for schizophrenia, The Cochrane Library,
  8. 8
    Simon Gilbody, Allan House, Trevor Sheldon, Outcome measures and needs assessment tools for schizophrenia and related disorders, The Cochrane Library,
  9. 9
    Manit Srisurapanont, Benchalak Maneeton, Narong Maneeton, Sudheer Lankappa, Rahul Gandhi, Quetiapine for schizophrenia, The Cochrane Library,
  10. 10
    Katja Komossa, Christine Rummel-Kluge, Sandra Schwarz, Franziska Schmid, Heike Hunger, Werner Kissling, Stefan Leucht, Risperidone versus other atypical antipsychotics for schizophrenia, The Cochrane Library,
  11. 11
    Ranganath Rattehalli, Mahesh B Jayaram, Risperidone versus placebo for schizophrenia, The Cochrane Library,
  12. 12
    Ranganath D Rattehalli, Mahesh B Jayaram, Michael Smith, Risperidone versus placebo for schizophrenia, The Cochrane Library,
  13. 13
    Christian Schwarz, Anja Volz, Chunbo Li, Stefan Leucht, Valproate for schizophrenia, The Cochrane Library,